Small-Vessel Heart Disease: When the Problem Is Below the Angiogram

Ninety percent of your coronary blood flow is controlled by vessels an angiogram cannot see. That is where a large share of women’s heart disease lives, and it has been called “normal” by clinicians reading reports that were never designed to find it.

The coronary circulation has two anatomically distinct layers. The epicardial arteries, the structures visible on standard angiography, carry blood toward the heart surface. The microvasculature, arterioles and capillaries ranging from 20 to 500 micrometers in diameter and too small to resolve on any catheterization imaging system, distributes that blood through the myocardium itself. These small vessels are not passive conduits. They regulate flow through active vasodilation and vasoconstriction in response to metabolic demand, endothelial signals, and autonomic tone. When this regulatory capacity fails, the result is ischemia in working muscle tissue while entirely open epicardial arteries produce an angiogram that reads as clean.

This is coronary microvascular dysfunction, and the standard cardiac workup will not find it.

The Mechanism

Under normal conditions, the coronary microvasculature dilates when the myocardium’s oxygen demand rises, whether from physical exertion, emotional stress, cold exposure, or metabolic activation. The primary mediator is endothelium-derived nitric oxide: endothelial cells lining the arterioles sense increased shear stress from rising flow demand and release nitric oxide, which diffuses into the underlying smooth muscle cells and triggers vasodilation. This endothelium-dependent pathway is the first mechanism and the one most vulnerable to dysfunction.

A second pathway, endothelium-independent vasodilation, involves direct smooth muscle response to pharmacological vasodilators such as adenosine. This pathway remains intact when the endothelium is dysfunctional, which is why testing both pathways independently is essential to characterizing what kind of microvascular problem a patient has.

Coronary flow reserve (CFR) is the ratio of maximal achievable coronary blood flow during pharmacological vasodilation to resting baseline flow. In normal physiology, the microvasculature can dilate enough to increase flow by 3.5 to 5 times above resting. A CFR below 2.0 to 2.5 indicates the small vessels cannot open far enough to meet demand. 4 / Promising The muscle supplied by those vessels experiences ischemia as demand rises, producing angina, breathlessness, and ECG changes identical to those produced by a fixed obstructive blockage upstream.

The index of microcirculatory resistance (IMR) measures the resistance the microvasculature generates at maximal vasodilation, using a pressure-temperature wire to calculate resistance from transit time and distal coronary pressure simultaneously. An IMR above 25 units indicates that even at maximal dilation, the small vessels are too resistant to allow normal flow. CFR and IMR together characterize two distinct aspects of microvascular physiology: the capacity to vasodilate and the structural resistance at maximal dilation. Both can be abnormal independently or together.

Neither appears on a standard angiography report. They require a different wire, additional time in the catheterization laboratory, and a physician who has ordered the measurements.

Microvascular spasm, a distinct mechanism from endothelial dysfunction, involves active vasoconstriction of small vessels in response to acetylcholine or other stimuli. It can coexist with impaired vasodilation or occur independently. Acetylcholine infusion during catheterization provokes this response and can produce chest pain and ECG changes in women with microvascular spasm who have completely normal resting anatomy and a clean routine angiogram. Without the acetylcholine test, the spasm is invisible.

What the Evidence Shows

The Women’s Ischemia Syndrome Evaluation (WISE) study, a National Heart, Lung, and Blood Institute-sponsored prospective cohort, enrolled women referred for coronary angiography for chest pain and found that approximately two-thirds had non-obstructive coronary arteries on angiography. 4 / Promising Among these women, abnormal CFR was documented in a substantial subset, and this physiologic finding correlated with ischemic findings on stress imaging, symptomatic burden, and, critically, long-term outcomes.

The WISE follow-up data, published by Shaw and colleagues in the Journal of the American College of Cardiology in 2006, showed that women with non-obstructive coronary artery disease and chest pain had significantly higher rates of major adverse cardiovascular events than asymptomatic controls without coronary artery disease. Hospitalization rates, cardiac procedure rates, and cardiac mortality were all elevated compared with what the “normal angiogram” label implied. The study directly contradicted the assumption that non-obstructive anatomy in symptomatic women was a benign finding.

Bairey Merz and colleagues from the WISE investigator group have published extensively on the sex-specific biology underlying this disparity. Estrogen supports endothelial nitric oxide synthase expression, which is the primary mechanism by which arterioles dilate in response to demand. Post-menopausal estrogen loss correlates with measurable reduction in coronary vasoreactivity, and the WISE data documented worsening ischemic burden in the peri-menopausal and post-menopausal window. Women develop CMD at younger ages relative to men developing obstructive atherosclerosis. 4 / Promising

Inflammatory conditions, more prevalent in women and including autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, independently damage the microvasculature through oxidative stress and endothelial injury. Ridker and colleagues demonstrated that high-sensitivity C-reactive protein, a marker of systemic inflammation, predicts cardiovascular events in women independently of traditional Framingham risk factors, with a publication in the New England Journal of Medicine in 2002. The WISE investigators documented that inflammatory markers correlate with the degree of microvascular dysfunction in their cohort. The inflammatory burden on the microvasculature is not a theoretical mechanism; it is measurable and is associated with clinical outcomes.

The CorMicA trial, published by Berry and colleagues in JACC Cardiovascular Interventions in 2019, tested whether stratifying women with angina and non-obstructive arteries by coronary function testing results and treating to the specific diagnosis changed outcomes. Women assigned to stratified treatment, who received therapy targeted to their specific microvascular or vasospastic mechanism, had significantly lower angina burden and better quality of life scores at 12 months compared with control patients managed conventionally. This trial established that diagnosing the specific functional abnormality is not academic; it changes treatment and treatment changes outcomes.

The ISCHEMIA trial, published in the New England Journal of Medicine in 2020, enrolled patients with stable angina and documented ischemia and compared routine invasive management with guideline-directed medical therapy. For many patients with stable ischemic heart disease, medical therapy was as effective as early revascularization for preventing MI and death. This finding is particularly relevant to CMD, where revascularization has no target: there is no plaque to stent in a patient whose disease is microvascular. Guideline-directed medical therapy, tailored to the specific functional mechanism, is not a consolation prize. It is the correct treatment for the disease present.

For CMD, the mechanism-targeted options include ACE inhibitors and angiotensin receptor blockers to improve endothelial function and reduce vascular inflammation; statins for endothelial stabilization independent of lipid lowering; beta-blockers to reduce demand during exertion; ranolazine for its effect on late sodium current, which reduces ischemia independently of heart rate or blood pressure; and calcium channel blockers when vasospasm is the predominant mechanism. None of these work maximally if the diagnosis is wrong or absent.

The History That Caused Harm: Cardiac Syndrome X

For several decades, women with exertional chest pain, normal epicardial arteries on angiography, and demonstrable ischemia on stress imaging were grouped under the label “Cardiac Syndrome X.” The term was descriptive at the time of its introduction in the 1970s because the mechanism was not yet understood. By implying a syndrome without defined pathophysiology, it also implied an uncertain or possibly benign prognosis, and clinical practice largely treated these patients as reassured rather than diagnosed.

The WISE long-term follow-up data, published by Shaw and colleagues in the Journal of the American College of Cardiology in 2006, directly contradicted the benign prognosis assumption. Women with CMD and non-obstructive coronary disease had elevated rates of MI, stroke, heart failure hospitalization, and cardiac death compared with asymptomatic controls. They had quality-of-life impairment indistinguishable from that of women with obstructive coronary artery disease. The “syndrome” had a mechanism, measurable physiological abnormalities, and real outcomes that matched or exceeded those of the better-known obstructive disease.

The term “Cardiac Syndrome X” is being replaced in cardiology literature and clinical guidelines by mechanistically specific terminology: coronary microvascular dysfunction when the small-vessel physiology is the primary abnormality, vasospastic angina when vasospasm is the documented mechanism, and INOCA (ischemia with non-obstructive coronary arteries) as the umbrella term for the broader phenotype. This is not merely a renaming exercise. Each of these diagnoses has a specific evaluation pathway, a specific physiological marker, and specific treatment targets. Using mechanism-specific terminology forces the evaluation that produces the diagnosis and opens the treatment pathway that follows.

A woman told she has “Cardiac Syndrome X” received a label. A woman told she has coronary microvascular dysfunction with impaired coronary flow reserve has a diagnosis, a physiological explanation for her symptoms, and a reason to begin mechanism-targeted treatment. The difference between those two statements is the functional testing her prior evaluation did not include.

Non-Invasive Imaging for CMD: PET and Stress CMR in the Evaluation Pathway

Invasive physiologic testing during cardiac catheterization, measuring CFR and IMR with a pressure-temperature wire, provides the most definitive characterization of coronary microvascular function. However, catheterization carries procedural risk and requires laboratory access. Non-invasive imaging alternatives can identify CMD with varying degrees of specificity and represent the practical first evaluation step for most patients.

Standard exercise or pharmacological stress ECG testing is poorly suited to detecting CMD. The classic criterion for test positivity, ST depression exceeding 1 mm in 2 or more leads, is calibrated to detect epicardial stenosis producing regional ischemia. CMD produces a diffuse subendocardial ischemia pattern that may cause only mild, diffuse ECG changes or no changes at all, even when perfusion imaging demonstrates a clear deficit. A negative stress ECG in a woman with exertional chest pain and risk factors for CMD is not an adequate evaluation of her microvascular function; it has answered a different diagnostic question.

Myocardial perfusion imaging with single-photon emission computed tomography (SPECT) is more sensitive than stress ECG but carries its own limitation in CMD: the global and balanced nature of microvascular ischemia can produce a perfusion pattern that appears normal or only mildly abnormal on relative perfusion maps. SPECT quantifies relative flow between segments; a microvasculature that dilates uniformly but inadequately will not generate the regional heterogeneity the technique is optimized to detect.

Positron emission tomography (PET) with absolute myocardial blood flow quantification overcomes this limitation. PET with rubidium-82 or nitrogen-13 ammonia allows absolute measurement of myocardial blood flow in milliliters per gram per minute at rest and during pharmacological stress, enabling direct calculation of coronary flow reserve without invasive catheterization. Murthy and colleagues published outcome data in the Journal of the American College of Cardiology in 2011, following 5,677 patients who underwent PET myocardial perfusion imaging with absolute flow quantification, and found that reduced CFR measured by PET was independently associated with cardiovascular death, with a hazard ratio of 3.6 per unit decrease in CFR. PET-measured CFR provides non-invasive quantification of the same physiological parameter that catheterization-based testing measures directly.

Stress cardiac MRI with first-pass adenosine perfusion sequences provides high-resolution perfusion imaging that is sensitive to the global subendocardial ischemia characteristic of CMD. In analyses comparing CMR with SPECT in women with suspected myocardial ischemia and non-obstructive arteries, CMR demonstrated superior sensitivity for detecting perfusion defects in the INOCA phenotype. Stress CMR also provides structural information, including late gadolinium enhancement for fibrosis characterization and T2 mapping for myocardial edema, in a single radiation-free examination. For women referred with exertional chest pain, known non-obstructive coronary anatomy, and suspected CMD, stress CMR with perfusion imaging is increasingly a preferred first-choice evaluation at specialized centers with dedicated INOCA programs.

What to Do This Week

1. If you have a history of chest pain, a positive stress imaging study showing a perfusion defect, and a cardiac catheterization report that documents non-obstructive arteries, ask your cardiologist specifically: “Were coronary flow reserve and microvascular resistance measured during my catheterization?” If the answer is no, ask whether invasive or non-invasive functional testing is indicated now. These are the measurements that would answer whether CMD is present.

2. Ask specifically about acetylcholine provocation testing if you have rest-predominant or cold-triggered chest pain. Vasospasm tends to occur at rest or with cold, emotional stress, or hyperventilation rather than with exertion alone. If your symptoms fit this pattern and your workup has not included acetylcholine testing, the vasospasm mechanism has not been evaluated.

3. If you are post-menopausal and your cardiac symptoms began or significantly worsened during the peri-menopausal or early post-menopausal period, note this explicitly when discussing your history. The temporal correlation with estrogen loss is clinically relevant to the probability of CMD and should be part of the formal history, not an aside.

4. Bring any prior stress test reports to your next appointment. A perfusion defect without a corresponding epicardial lesion is the key finding that points toward CMD and should prompt functional evaluation rather than re-categorization as a false positive result.

5. Ask whether a PET stress test with coronary flow reserve measurement or a cardiac MRI stress perfusion study is appropriate if you have not had imaging-based stress testing. Standard exercise ECG stress testing is not sensitive for CMD. It misses the subendocardial ischemia that microvascular disease produces, which requires perfusion imaging rather than surface ECG to detect.

CMD is measurable. The measurements require knowing to perform them, but they are available at specialized centers, and an increasing number of academic cardiology programs have dedicated INOCA or women’s heart programs where this testing is part of the standard evaluation. The mechanism is specific. The treatments are specific. The first step is confirming the diagnosis exists before the targeted treatments can be assigned to it.

A woman who has been told her angiogram was clean and her heart is fine, who still has chest pain with exertion and rest, who has had symptoms dismissed as anxiety or musculoskeletal or gastrointestinal for years, has not had her coronary function evaluated. That is not a reassurance she received. It is an evaluation that has not yet been done.